Anti-TBX19 monoclonal antibody in pituitary tumor research
October 2022 (Department of Neurosurgery, Yonsei University College of Medicine, Seoul, South Korea)
TBX19 (also referred to as TPIT) is a transcription factor that regulates developmental processes and is expressed almost exclusively in the pituitary gland, where it interacts with POMC (pro-opiomelanocortin).
One peptide produced from the POMC protein is the adrenocorticotropic hormone (ACTH) which in turn stimulates the release of cortisol that helps maintain blood sugar levels, protects the body from stress, and suppresses inflammation.
The Anti-TBX19 (AMAb91409) monoclonal antibody is one of our top 10 best-sellers.
It has been used by researchers worldwide mainly for its involvement in pituitary and salivary gland tumors (see list of recent references below).
For example, a 2021 study highlights its role in the new cell lineage-based classification for pituitary adenomas proposed by the World Health Organization (WHO), in which transcription factors play a significant role as key classifiers.
✅ Sumislawski P, et al. ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX, and PTEN mutations: Case report and review of the literature. Endocrine, 76, 228–236 (2022)
✅ Hong SW, et al. Clinical Relevance of New World Health Organization Classification System for Pituitary Adenomas: A Validation Study With 2-Year Experience. Front Oncol, 11:739290 (2021)
✅ Sakata K, et al. Primary Pituitary Adenoid Cystic Carcinoma: A Rare Salivary Gland-Like Tumor in the Sella.
Head Neck Pathol, 15(4):1289-1298 (2021)
✅ Casar-Borota O, et al. Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.
J Clin Endocrinol Metab, 106(4):1183-1194 (2020)
✅ Sakata K, et al. Pituitary Gangliocytoma Producing TSH and TRH: A Review of “Gangliocytomas of the Sellar Region”.
J Clin Endocrinol Metab, 105(10):3109-3121 (2020)